BioSpace News Archive

Shenzhen Chipscreen Biosciences’ licensing partner, HUYABIO International (HUYABIO™), today announced the regulatory approval for Chidamide (Tucidinostat, also known as Epidaza ®, Hiyasta®, HBI-8000) monotherapy for the treatment of relapsed or refractory (R/R) PTCL by the Ministry of Health, Labour and Welfare in Japan.

Cepheid actively monitors COVID-19 virus mutations and is well prepared to support detection of the “Omicron” B.1.1.529 variant with its PCRplus-based Xpert® coronavirus tests.

End-of-phase-2 response from the US regulatory agency (FDA) provides guidance and a path forward to advance ABX464 into a phase 3 clinical program in ulcerative colitis (UC).

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the expansion of the KYPROLIS regimen.

[01-December-2021] MIAMI , Dec. 1, 2021 /PRNewswire/ -- Gaumard Scientific Co., an industry leader of simulation technology for healthcare education and training, today announced that the company’s Ultrasound and Pediatric Emergency POCUS/eFAST Scenario Courseware is honored as a 2021 EMS World Innovation Awards Winner.

180 Life Sciences Corp. today announced that Professor Jagdeep Nanchahal presented a keynote address entitled ‘Re-purposing anti-TNF for Dupuytren’s Disease’ at the 2021 International Dupuytren Symposium on Wednesday, December 1, 2021.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced Janssen Biotech, Inc. (Janssen) received U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with Kyprolis® (carfilzomib) and dexamethasone (Kd) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.

Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced the closing of its previously announced registered direct offering with certain institutional investors for the purchase and sale of 5,880,000 shares of common stock for $1.50 per share (i.e., for aggregate gross proceeds of $8,820,000).

Researchers at the Nagourney Cancer Institute and Metabolomycs, Inc. announced in issue of PLOS ONE a study that showed that COVID-19 related illness severity and death can be predicted by a blood test that is conducted at the time of diagnosis.

An orphan drug is a pharmaceutical product which is utilized in the diagnosis, prevention, and treatment of rare and serious diseases.